Welcome to our dedicated page for Edap Tms SEC filings (Ticker: EDAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EDAP TMS SA (Nasdaq: EDAP) SEC filings page on Stock Titan provides centralized access to the company’s Form 6-K current reports and other U.S. regulatory disclosures. EDAP uses these filings to report unaudited quarterly financial results, business updates and material agreements related to its robotic energy-based therapies and High-Intensity Focused Ultrasound (HIFU) platforms.
In its 6-K filings, EDAP presents condensed consolidated statements of operations and balance sheets, detailing revenue from sales of medical equipment, recurring revenue programs and leases, and sales of spare parts, supplies and services. These filings break out performance in the company’s core HIFU business and non-core ESWL and Distribution segments, and include information on gross profit, operating expenses, operating loss and net loss. They also provide narrative discussion of HIFU revenue growth, system placements and procedure volumes.
EDAP’s SEC reports are also the primary source for regulatory and strategic disclosures. Recent 6-Ks describe the company’s transition from foreign private issuer status to U.S. domestic filer status, effective January 1, 2026, and outline the implications for SEC reporting and Nasdaq listing requirements. Other filings disclose a multi-tranche credit facility with the European Investment Bank, including the intended use of proceeds to expand the Focal One Robotic HIFU platform and develop new clinical indications.
Regulatory filings incorporate full text of press releases on topics such as FDA 510(k) clearance for enhancements to the Focal One HIFU system, reimbursement decisions in France for Focal One Robotic HIFU procedures in prostate cancer, and recognition of the Focal One platform by professional societies. These documents also reference key clinical studies, including the HIFI and FARP trials, as part of the company’s description of its clinical evidence base.
On Stock Titan, EDAP filings are supplemented with AI-powered summaries that highlight the main points of each document, helping readers quickly identify changes in revenue guidance, financing arrangements, reimbursement developments or reporting status. Users can review new filings as they are posted to EDGAR and revisit historical 6-Ks and other forms to analyze how EDAP’s HIFU-focused strategy, financial profile and regulatory environment have evolved over time.
EDAP TMS S.A. (EDAP) reported that the U.S. Food and Drug Administration has granted 510(k) clearance for new ultrasound imaging and workflow enhancements to its Focal One High Intensity Focused Ultrasound (HIFU) system used in robotic focal therapy for prostate cancer. The clearance covers advanced ultrasound imaging, streamlined treatment planning, and an optimized user interface for the recently launched Focal One i platform.
EDAP states that the next generation ultrasound imaging engine provides real-time visualization and supports the potential development of AI-driven algorithms to assist surgeons with tissue ablation visualization and treatment evaluation. Management describes this as an important technical milestone that further strengthens Focal One’s product roadmap and reinforces its global leadership positioning in focal therapy.
EDAP TMS (EDAP) highlights its position as a global leader in robotic high-intensity focused ultrasound (HIFU) for prostate cancer, BPH and endometriosis, supported by growing clinical use and reimbursement. The company reports revenue of $16.1 million for the three months ended September 30, 2025, up from $14.4 million, with gross margin improving to 43.0% from 39.4%. HIFU revenue rose to $7.7 million from $4.9 million, while distribution and ESWL lines declined.
EDAP remains loss-making, with operating loss of $5.7 million and net loss of $5.8 million for the quarter, slightly better than a year earlier. For the nine-month period, revenue was $48.8 million with net loss of $19.8 million. Cash and cash equivalents were $12.4 million as of September 30, 2025. The company reports 76 Focal One systems installed in the U.S. and emphasizes expanding indications, strong clinical evidence, and favorable Medicare reimbursement as foundations for future growth.
EDAP TMS (EDAP) reported third-quarter 2025 results highlighting continued momentum in its HIFU franchise. HIFU revenue was €6.7 million (US $7.7 million), up 49% year over year, as Focal One system sales doubled to six and U.S. procedures rose 15%. Total revenue reached €13.9 million (US $16.1 million), up 6% from the prior year period.
Profitability metrics improved: gross profit was €6.0 million with a 43% margin versus 39% a year ago, while operating loss narrowed to €4.9 million and net loss to €5.0 million (€0.13 per share) from €6.4 million (€0.17 per share). Year-to-date, HIFU revenue was €21.3 million, up 42%, and total revenue was €43.5 million, down 0.7%. Cash and cash equivalents were €10.6 million as of September 30, 2025.
Management reiterated 2025 guidance: core HIFU revenue growth of 26%–34%, with non-core ESWL and Distribution revenue declining 25%–30%. The company also finalized a €36 million European Investment Bank credit facility, with €11 million from the first tranche received.
EDAP TMS S.A., a France-based company, filed a Form S-8 registration statement to register equity awards under two employee incentive plans: the 2025-2 Restricted Stock Unit (Free Share) Plan and the 2025 Share Subscription Option Plan. These plans are designed to grant free shares and share options to eligible participants, aligning their interests with the company’s long-term performance.
The filing incorporates by reference EDAP’s 2024 annual report on Form 20-F and certain Form 6-K reports, so future SEC filings will automatically update the information used for the plans. The company also describes director and officer liability insurance consistent with French law and includes standard SEC undertakings and signatures from senior executives and directors authorizing the registration.
EDAP TMS reports that its Q2 2025 revenue rose to $18.4M from $17.0M a year earlier, driven by strong growth in its Focal One robotic HIFU prostate cancer business. Gross profit increased to $7.8M, with gross margin improving to 42.5% from 37.5%, while operating loss held at $(6.6)M. Net loss was $(6.4)M, or $(0.17) per share.
By segment for the quarter, HIFU revenue reached $9.7M (up 89%), ESWL was $1.8M (down 27%), and distribution revenue was $6.9M (down 26%). As of June 30, 2025, cash and cash equivalents were $19.1M versus $32.4M a year earlier, and shareholders’ equity was $32.7M versus $51.0M.
The company highlights more than 350 Focal One HIFU clinical sites and 73 systems in the U.S. at the end of Q2 2025, strong reimbursement for HIFU procedures, and expanding clinical programs in prostate cancer, benign prostatic hyperplasia, and endometriosis.
EDAP TMS reported a major milestone as the French Ministry of Health granted national reimbursement for its Focal One robotic High Intensity Focused Ultrasound (HIFU) procedure to treat prostate cancer. Coverage in France applies to eligible patients both as a primary treatment for localized prostate cancer and as a salvage option after radiotherapy. This makes the non-invasive Focal One therapy accessible under France’s universal Social Security system.
The company links this decision to positive clinical evidence from the HIFI Study sponsored by the French Urology Association, as well as Level 1 evidence from the FARP Study presented at the American Urological Association meeting. Reimbursement became effective on September 1, 2025. Management believes that winning reimbursement in one of Europe’s largest healthcare markets may help support future reimbursement decisions in other European countries and drive broader adoption of Focal One.
EDAP TMS SA reported strong commercial momentum in HIFU (high-intensity focused ultrasound), with Focal One net placements up +140% year-over-year and HIFU revenue up 76.8% year-over-year. Management raised 2025 HIFU revenue growth guidance to a 26%–34% range from a prior 16%–25% range, and executed a letter of intent with the European Investment Bank for a €36 million credit facility to support HIFU growth and strategic expansion.
The company announced it will become a U.S. domestic filer effective January 1, 2026, beginning SEC reporting and Nasdaq requirements. Additional milestones include presentation of positive 3-year randomized controlled trial outcomes for focal ablation versus radical prostatectomy and the launch of the new Focal One i Robotic HIFU System.
EDAP TMS entered into a letter of intent for a EUR 36 million credit facility with the European Investment Bank to support its robotic energy-based therapy business. The funding is intended to expand adoption of the Focal One® Robotic HIFU system in focal therapy for early-stage prostate cancer and to accelerate development of new clinical indications. Pending final legal documentation, the facility is expected to close no later than the end of calendar year 2025 and is described as low-interest funding that can be drawn in tranches as needed.